- The FDA approves Senseonics Holdings' (NYSE:SENS +1.2%) Eversense Continuous Glucose Monitoring (CGM) System. The device features an implantable sensor that lasts up to 90 days.
- Management will host a conference call today at 4:30 pm ET to discuss the approval and market launch plans.
- Related tickers: (TNDM -2.2%)(DXCM -1%)(ABT -0.9%)(MDT -0.1%)(PODD -1.9%)
FDA OKs Senseonics Eversense CGM device; shares up 1%
Recommended For You
About SENS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SENS | - | - |
Senseonics Holdings, Inc. |